Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-09-04
2000-01-11
Krass, Frederick
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
4241851, 4241841, 4241981, 424 937, A01N 4378, A61K 31425
Patent
active
060136596
ABSTRACT:
This invention pertains to methods of treating cancer by reducing tumor colony number in a mammalian host using benzothiazole activated natural killer cells and interleukin-2. The benzothiazoles are of the formula I: ##STR1## wherein R.sub.1 is 4-OMe and R.sub.2 is 4-tBu or 4-CF.sub.3.
REFERENCES:
patent: 3669979 (1972-06-01), Freyermuth
patent: 4556411 (1985-12-01), Baum et al.
patent: 4705861 (1987-11-01), Furstenwerth et al.
patent: 4910211 (1990-03-01), Imamura et al.
patent: 5236619 (1993-08-01), Iwaki et al.
"Enhanced anti-metastatic efficacy of IL-2 activated NK (A-NK) cells with novel benzothiazoles" R. H. Goldfarb et al, Anticancer Research, submitted, 1998.
"Enhanced anti-metastatic efficancy of IL-2 activated NK (A-NK) cells with novel benzothiazoles", R. H. Goldfarb et al, FASEB J., 12:A475:2763, 1998.
"Preclinical studies of IL-2 activated natural killer effector cells for locoregional therapy of metastatic cancer", R. H. Goldfarb, Journal of Infusional Chemotherapy, 4:77-82, 1994.
"Augmentation of IL-2 activated natural killer cell adoptive immunotherapy with cyclophosphamide", R. H. Goldfarb et al, Anticancer Research, 18:1441-1446, 1998.
"Augmentation of IL-2 natural killer cell adoptive immunotherapy with cyclosphosphamide", R. H. Goldfarb et al, Proceedings of the American Association for Cancer Research Meeting, 37:480, 1996.
"Flavone acetic acid enhances accumulation of IL-2 activated NK cells within established metastases", R. P. Kitson et al, In Vivo, in press, 1998.
Flavone acetic acid enhancement of IL-2 activated NK cell accumulation within established metastases as assessed by quantitative image analysis, R. P. Kitson et al, Proceedings of the American Association for Cancer Research Meeting, 35:480, 1994.
"IL-2 activated NK cells: Interactions with tumor cells and endothelial cells within tumor metastases: Necessary but not sufficient for therapy of established metastases?", R. H. Goldfarb et al, Nat. Immunity, 13:228-229, 1994.
Natural Immunity, 1994:131-140, "Natural Killer Cells and Gene Therapy: Potential of Gene Transfection for Optimizing Effector Cell functions and for Targeting Gene Products into Tumor Metastases".
"Localization of Immune Effector Cells to Tumor Metastases", Ronald H. Goldfarb, Theresa L. Whiteside, Tumor Immunology and Cancer Therapy, 1994, pp. 149-158.
"Accumulation of Adoptively Transferred Adherent, Lymphokine-activated Killer Cells in Murine Metastases",P. Basse, et al., vol. 174, Aug. 1991, 479-488.
Tissue distribution of adoptively transferred adherent lymphokine-activated killer cells assessed by different cell labels, P. Basse, et al., Cancer Immunology Immunotherapy, 1992, 34:221-227.
Establishment of Cell-to-Cell Contact by Adoptively Transferred Adherent Lymphokine-Activated Killer Cells With Metastatic Murine Melanoma Cells, P.Basse et al., Journal of the National Cancer Institute, vol. 83, No. 13, Jul. 3, 1991, pp. 944-950.
"Tissue Distribution of Adoptively Transferred Adherent LAK Cells: Role of the Route of Administration", Natural Immunity, 1992, 11:193-202.
"Accumulation of Adoptively Transferred A-NK Cells in Murine Metastases: Kinetics and Role of Interleukin-2", P.H. Basse et al., in vivo, 8:17-24 (1994).
"Novel Disease-Modifying Antirheumatic Drugs. I. Synthesis and Antiarthritic Activity of 2-(4-Methylphenyl)benzothiazoles", Hori et al., Chem. Pharm. Bull. 40(9), pp. 2387-2390 (1992).
"Structural Studies on Bioactive compounds, 23, Synthesis of Polyhydroxylated 2-Phenylbenzothiazoles and a Comparison of Their Cytotoxicities and Pharmacological Properties with Genistein and Quereetin", Stevens et al., J. Med. Chem, pp. 1689-1695, (1994), 37.
"Augmentation of IL-2 Activated Natural Killer Cell Adoptive Immunotherapy with Cyclophosphamide", Goldfarb et al., Anticancer Research 18, pp. 1441-1446, (1998).
Goldfarb Ronald H.
Ohashi Masami
Yoshino Kohichiro
Krass Frederick
University of Pittsburgh
LandOfFree
Methods of reducing tumor colony number using novel benzothiazol does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of reducing tumor colony number using novel benzothiazol, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of reducing tumor colony number using novel benzothiazol will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1462603